|Titre :||Public expenditure on drugs in the European Union 2000-2004. Contribution to the evaluation of the EU action plan on drugs (2000-2004)|
|Auteurs :||OEDT = EMCDDA|
|Type de document :||Rapport|
|Editeur :||Lisbon : OEDT / EMCDDA, 2004|
|Format :||44 p.|
|Discipline :||SAN (Santé publique / Public health)|
Thésaurus TOXIBASEEVALUATION ; PLANIFICATION SANITAIRE ; POLITIQUE ; DEPENSES DE SANTE ; DEPENSE
Thésaurus GéographiqueEUROPE ; UNION EUROPEENNE
A crucial element in evaluating drug policy, and an important indicator of political commitment to the drugs issue, is the estimation of governments’ expenditure to counter the problem. This thematic paper offers an overview of the state of research on public expenditure in the drugs field in the light of the new EU strategy and action plan.
Research into public expenditure on drugs aims to examine how much the government spends to counter the drugs problem in general, what budget is attributed to specific areas and how this is sustained over time. Only a few EU Member States offer data on the cost of drug policy and those who do so report that the lion’s share of the drug budget is dedicated to law enforcement, with prevention, one of the top priorities of drug policy in the EU and globally, receiving only a small portion.
Research to date has pointed to the lack of comparability between studies, highlighting the need for consensus on conceptual issues, such as how expenditure should be classified and how data should be collected and used for estimation, says the paper. The EU should not only promote further research into public expenditure but also favour a common EU framework for research. High-quality information on drug expenditure, that would allow for sound cost–benefit analyses, is urgently needed in the EU.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||EMCDDA 'Strategies and Impact' Programme, Lisbon, Portugal|
|Titre précédent :|
|Titre suivant :|
Documents numériques (1)
Adobe Acrobat PDF